Syncom Formulations (India) Limited — Important, 11-11-2024: Financial Result Updates

**Consolidated Financial Results:**

Syncom Formulations reported robust growth with Q2 revenue from operations reaching ₹10,290.42 crore, a significant increase from ₹6,993.80 crore YoY, translating to a growth of approximately 47.4%. Key drivers include strong performance in pharmaceuticals and improved market penetration.

Net profit for the quarter stood at ₹1,108.52 crore, up from ₹763.25 crore last year, reflecting an increase of about 45.3%. The Earnings Per Share (EPS) rose to ₹0.18 from ₹0.08, bolstered by operational efficiency despite some fluctuations in material costs.

Operational costs increased 12.8% to ₹9,161.27 crore, attributed mainly to higher employee expenses and raw material prices. The company's efforts in cost control appear effective, as profit before tax before exceptional items showed resilience at ₹1,485.07 crore.

The balance sheet remains solid with total assets reported at ₹37,244.51 crore, down slightly from ₹40,466.39 crore but reflects strong liquidity management with cash and equivalents at ₹25.02 crore.

The outlook indicates a continued focus on operational efficiency and market expansion. With a healthy profit growth trajectory and strategic initiatives in place, a cautious buy sentiment is supported, anticipating sustained market demand.